Bristol-Myers Squibb Co. (BMY) Ends Development of Opdivo Combo, Morgan Stanley Reiterates Underweight
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Underweight rating and $64.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
